1-14 of 14
Joel D. Leverson, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Identification of Recurrent Genomic Alterations in the Apoptotic Machinery in CLL Patients Treated with Venetoclax Monotherapy

Brenda J Chyla, PhD, Relja Popovic, PhD, Charles Lu, PhD, Fengjiao Dunbar, PhD, Danjuma Quarless, PhD, Kenneth Robinson, MS, Scott Warder, PhD, Amanda Jacobson, PhD, Lang Zhou, PhD, Andrew Souers, PhD, Jeffrey Waring, PhD, Anahita Bhathena, PhD, Joel D. Leverson, PhD, Su Young Kim, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 172.
https://doi.org/10.1182/blood-2019-127458
Published: 2019
Journal Articles

Immune Profiling of Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Dexamethasone (VenDex), Daratumumab and Dexamethasone (VenDd), and Daratumumab, Bortezomib and Dexamethasone (VenDVd)

Deeksha Vishwamitra, Christine Mantis, PhD, Dipica Haribhai, PhD, Tamar Uziel, PhD, Joel D. Leverson, PhD, James M. Pauff, MD PhD, Orlando F. Bueno, MD PhD, Paulo C. Maciag, MD PhD, Jeremy A. Ross, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1896.
https://doi.org/10.1182/blood-2019-128672
Published: 2019
Journal Articles

Pevonedistat, a Nedd-8 Activating Enzyme Inhibitor, Upregulates NOXA to Increase Effectiveness of Azacitidine and Venetoclax in Preclinical Models of Acute Myelogenous Leukemia

Brianna N Smith, MD MS, Dan Cojocari, PhD BSc, Julie J Purkal, MA, Maria Arrate, MSc, Haley E. Ramsey, PhDMSc, Joel D. Leverson, PhD, Erwin Boghaert, MS, MD, Darren C. Phillips, PhD, Michael R. Savona, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1380.
https://doi.org/10.1182/blood-2019-123068
Published: 2019
Journal Articles

The BCL-2-Selective Inhibitor Venetoclax Spares Activated T-Cells during Anti-Tumor Immunity

Rebecca Mathew, PhD, Dipica Haribhai, PhD, Fred Kohlhapp, PhD, Ryan Duggan, Paul Ellis, Jacob J Riehm, Valerie A Robinson, Yan Y Shi, Anahita Bhathena, PhD, Joel D. Leverson, PhD, William N Pappano, Cherrie K Donawho, PhD, Tamar Uziel, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3704.
https://doi.org/10.1182/blood-2018-99-113134
Published: 2018
Journal Articles

5-Azacytidine Induces NOXA and PUMA Expression to Prime AML Cells for Venetoclax-Mediated Apoptosis

Dan Cojocari, PhD BSc, Sha Jin, MS, Julie J Purkal, MA, Relja Popovic, PhD, Nari N Talaty, PhD, Yu Xiao, MS, Larry R Solomon, PhD, Erwin Boghaert, MS, MD, Joel D. Leverson, PhD, Darren C. Phillips, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2644.
https://doi.org/10.1182/blood-2018-99-111985
Published: 2018
Journal Articles

Combination of Enasidenib and Venetoclax Shows Superior Anti-Leukemic Activity Against IDH2 Mutated AML in Patient-Derived Xenograft Models

Severine Cathelin, PhD, David Sharon, PhD, Amit Subedi, PhD, Dan Cojocari, PhD BSc, Darren C. Phillips, PhD, Joel D. Leverson, PhD, Kyle MacBeth, PhD, Brandon Nicolay, Rohini Narayanaswamy, Sebastien Ronseaux, Guowen Liu, PhD, Steven M Chan, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 562.
https://doi.org/10.1182/blood-2018-99-119688
Published: 2018
Journal Articles

FLT3-ITD Activation Mediates Resistance to the BCL-2 Selective Antagonist, Venetoclax, in FLT3-ITD Mutant AML Models

Raghuveer Singh Mali, PhD, Elisabeth A. Lasater, PhD, Kelly Doyle, Ritu Malla, Erwin Boghaert, Andrew Souers, Joel D. Leverson, PhD, Deepak Sampath, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1348.
https://doi.org/10.1182/blood.V130.Suppl_1.1348.1348
Published: 2017
Journal Articles

Alvocidib Enhances Venetoclax Sensitivity in Unfavorable-Risk Multiple Myeloma Cells In Vitro and In Vivo

Liang Zhou, PhD, Yu Zhang, PhD, Deepak Sampath, PhD, Joel D. Leverson, PhD, Yun Dai, MD, Maciej Kmieciak, Matthew Nguyen, Robert Z. Orlowski, MD PhD, Steven Grant, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2540.
https://doi.org/10.1182/blood.V130.Suppl_1.2540.2540
Published: 2017
Journal Articles

Combinatorial Treatment of Chronic Lymphocytic Leukemia with Ibrutinib and Venetoclax Is Superior to Treatment with Single Agents in the TCL1 Mouse Model

Erik Slinger, PhD, Sriram Balasubramanian, PhD, Joel D. Leverson, PhD, Eric Eldering, Arnon P. Kater, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3018.
https://doi.org/10.1182/blood.V130.Suppl_1.3018.3018
Published: 2017
Journal Articles

Do Statins Enhance the Anti-Cancer Activity of Venetoclax?

Andrew W. Roberts, MS, Tu Xu, PhD, Jia Jia, PhD MBA, Suresh Agarwal, MS, PhD RPh, Ahmed Hamed Salem, PhD, Richard J. Bellin, MS, Lloyd T. Lam, PhD, Joel D. Leverson, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1737.
https://doi.org/10.1182/blood.V130.Suppl_1.1737.1737
Published: 2017
Journal Articles

A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)

Marina Konopleva, MD PhD, Daniel A. Pollyea, MD MS, Jalaja Potluri, MD, Brenda J. Chyla, PhD, Todd Busman, MS, Evelyn McKeegan, PhD, Ahmed Salem, PhD, Ming Zhu, PhD, Justin L. Ricker, MD PhD, William Blum, MD, Courtney D. DiNardo, MD, Martin Dunbar, DRPH, Rachel Kirby, Nancy Falotico, Joel D. Leverson, PhD, Rod A. Humerickhouse, MD PhD, Mack Mabry, MD, Richard M. Stone, MD, Hagop M. Kantarjian, MD, Anthony G. Letai, MD PhD
Journal: Blood
Blood (2014) 124 (21): 118.
https://doi.org/10.1182/blood.V124.21.118.118
Published: 2014
Journal Articles

CDK9 Inhibition Reverses Resistance to ABT-199 (GDC-0199) By Down-Regulating MCL-1

Jun Chen, MDPhD, Sha Jin, MS, Paul Tapang, Stephen K Tahir, PhD, Morey Smith, John Xue, Haichao Zhang, PhD, Wenqing Gao, PhD, Yunsong Tong, PhD, Richard Clark, Justin L. Ricker, MD PhD, Thomas D Penning, PhD, Daniel H Albert, PhD, Darren C Phillips, PhD, Andrew J Souers, PhD, Joel D. Leverson, PhD
Journal: Blood
Blood (2014) 124 (21): 2161.
https://doi.org/10.1182/blood.V124.21.2161.2161
Published: 2014
Journal Articles

Activation of p53 By Novel MDM2 Antagonist RG7388 Overcomes AML Inherent and Acquired Resistance to Bcl-2 Inhibitor ABT-199 (GDC-0199)

Rongqing Pan, MS, Kensuke Kojima, MD PhD, Zhuanzhen Zheng, MD PhD, Vivian R Ruvolo, MA, Gwen Nichols, MD, Joel D. Leverson, PhD, Markus Dangl, PhD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD
Journal: Blood
Blood (2014) 124 (21): 2162.
https://doi.org/10.1182/blood.V124.21.2162.2162
Published: 2014
Journal Articles

Expression of Bcl-2 Pro-Survival Family Proteins Predicts Pharmacological Responses to ABT-199, a Novel and Selective Bcl-2 Antagonist, in Multiple Myeloma Models

Deepak Sampath, PhD, Elizabeth Punnoose, PhD, Erwin R. Boghaert, PhD, Lisa Belmont, PhD, Jun Chen, PhD, Franklin Peale, MD, PhD, Nguyen Tan, Walter Darbonne, Peng Yue, PhD, Jason Oeh, Leslie Lee, Wayne J. Fairbrother, PhD, Andrew J. Souers, PhD, Steve W. Elmore, PhD, Joel D. Leverson, PhD
Journal: Blood
Blood (2012) 120 (21): 5028.
https://doi.org/10.1182/blood.V120.21.5028.5028
Published: 2012